Amanda Woo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Amanda Woo has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Bremy Alburquerque
Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, USA
1 shared publication Brian Dobosh
Synthetic Biology Center, Massachusetts Institute of Technology, Cambridge, MA, USA
1 shared publication- Brian Teague
Department of Biology, University of Wisconsin
1 shared publication Douglas Densmore
Department of Biomedical Engineering, Boston University, Boston, MA, USA
1 shared publicationEly Porter
Synthetic Biology Center, Massachusetts Institute of Technology, Cambridge, MA, USA
1 shared publicationJacob Beal
Raytheon BBN Technologies, Cambridge, MA, USA
1 shared publication
Latest Publications
- 16 October 2018
- Published by Springer Nature in Nature Chemical Biology
- Vol. 14 (11) , 1043-1050
Small-molecule-based regulation of RNA-delivered circuits in mammalian cells
Synthetic mRNA is an attractive vehicle for gene therapies because of its transient nature and improved safety profile over DNA. However, unlike DNA, broadly applicable methods to control expression from mRNA are lacking. Here we describe a platform for small-molecule-based regulation of expression from modified RNA (modRNA) and self-replicating RNA (replicon) delivered to mammalian cells. Specifically, we engineer small-molecule-responsive RNA binding proteins to control expression of proteins from RNA-encoded genetic circuits. Coupled with specific modRNA dosages or engineered elements from a replicon, including a subgenomic promoter library, we demonstrate the capability to externally regulate the timing and level of protein expression. These control mechanisms facilitate the construction of ON, OFF, and two-output switches, with potential therapeutic applications such as inducible cancer immunotherapies. These circuits, along with other synthetic networks that can be developed using these tools, will expand the utility of synthetic mRNA as a therapeutic modality.
- 16 October 2018
- Published by Springer Nature in Nature Chemical Biology
- Vol. 14 (11) , 1043-1050
Small-molecule-based regulation of RNA-delivered circuits in mammalian cells
Synthetic mRNA is an attractive vehicle for gene therapies because of its transient nature and improved safety profile over DNA. However, unlike DNA, broadly applicable methods to control expression from mRNA are lacking. Here we describe a platform for small-molecule-based regulation of expression from modified RNA (modRNA) and self-replicating RNA (replicon) delivered to mammalian cells. Specifically, we engineer small-molecule-responsive RNA binding proteins to control expression of proteins from RNA-encoded genetic circuits. Coupled with specific modRNA dosages or engineered elements from a replicon, including a subgenomic promoter library, we demonstrate the capability to externally regulate the timing and level of protein expression. These control mechanisms facilitate the construction of ON, OFF, and two-output switches, with potential therapeutic applications such as inducible cancer immunotherapies. These circuits, along with other synthetic networks that can be developed using these tools, will expand the utility of synthetic mRNA as a therapeutic modality.